机构：[1]Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute andHospital, National Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention andTherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China,[2]Department of MedicalOncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,[3]Department of Otolaryngology Head and Neck Surgery, Beijing Tongren Hospital, Capital MedicalUniversity / Key Laboratory of Otolaryngology Head and Neck Surgery, Ministry of Education,Beijing Institute of Otolaryngology, Beijing, China,首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Head and Neck Surgery, Institute of Cancer andBasic Medicine (ICBM), Chinese Academy of Sciences.Cancer Hospital of the University of ChineseAcademy of Sciences.Zhejiang Cancer Hospital, Hangzhou, China,浙江省肿瘤医院[5]Department of Head, Neckand Thyroid Surgery, Zhejiang Provincial People’s Hospital, People’s Hospital of Hangzhou MedicalCollege, Hangzhou, China,[6]Head and Neck Surgery (Department), Jiangsu Cancer Hospital(Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital),Nanjing, China,[7]Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China,[8]Head and Neck Surgery, Gansu Provincial Cancer Hospital, Lanzhou, China,[9]Head and NeckSurgery Department I, Hunan Cancer Hospital, Changsha, China,[10]Thyroid Surgery Ward, HarbinMedical University Cancer Hospital, Harbin, China,[11]Department of Medical Oncology, Jilin CancerHospital, Changchun, China,[12]Head and Neck Department, Tumor Hospital of China MedicalUniversity, Liaoning Tumor Hospital & Institute, Shenyang, China,[13]Head and Neck Surgery, FujianCancer Hospital, Fuzhou, China,[14]Thyroid & Head and Neck Surgery, Henan Cancer Hospital,Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China,河南省肿瘤医院[15]Thyroid Surgery, WestChina Hospital, Sichuan University, Chengdu, China,[16]Department of Thyroid Surgery, FirstAffiliated Hospital of Kunming Medical University, Kunming, China,外科科室普通外科普通外五科(甲状腺疾病诊疗中心)昆明医科大学附属第一医院[17]Head and Neck Surgery,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, ChineseAcademy of Medical Sciences and Peking Union Medical College, Beijing, China,[18]Department for VIP, National Cancer Center/National Clinical Research Center for Cancer/CancerHospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China,[19]Breast & Thyroid Surgery, Tianjin Union Medical Center, Tianjin, China
BackgroundMedullary thyroid carcinoma (MTC) is a rare type of thyroid cancer; however, it accounted for 13.4% of the disease-specific mortalities. ALTER01031 (NCT02586350) was a randomised, placebo-controlled phase 2b trial that evaluated the efficacy and safety of anlotinib in locally advanced or metastatic MTC. This post hoc analysis aimed to evaluate the efficacy and safety of anlotinib in older patients and those with bone metastases using ALTER01031. MethodsIn ALTER01031, anlotinib significantly prolonged the median progression-free survival (PFS) from 11.1 months to 20.7 months compared with placebo in the whole population. Patients who were older (>= 50 years) or had bone metastases were selected. PFS and overall survival (OS) were estimated and compared between patients receiving anlotinib or placebo in each subgroup. A sub-analysis of tumour response and safety was also performed. ResultsPatients with older age or bone metastases experienced rapid disease progression as the median PFS was 6.8 months and 7.0 months respectively in the placebo group. Anlotinib significantly improved the median PFS to 17.5 months (P = 0.002) and 20.7 months (P = 0.029) with hazard ratio (HR) of 0.31 (95% CI, 0.15-0.68) and 0.44 (95% CI, 0.20-0.94) compared with placebo. Significant benefit in OS was observed in patients with older age after a longer follow-up (HR = 0.47 [95% CI, 0.22-0.99], P = 0.041). The safety profile of these subgroups was similar to that of the entire population. ConclusionThis sub-analysis demonstrated significant survival benefits and favourable safety of anlotinib in patients with MTC who had old age or bone metastases, supporting the feasibility of anlotinib in these patients.
基金：
Chia Tai TianQing Pharmaceutical Group Co., Ltd.; [ALTER01031]
第一作者机构：[1]Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute andHospital, National Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention andTherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China,
共同第一作者：
通讯作者：
通讯机构：[1]Department of Thyroid and Neck Oncology, Tianjin Medical University Cancer Institute andHospital, National Clinical Research Center for Cancer. Key Laboratory of Cancer Prevention andTherapy, Tianjin’s Clinical Research Center for Cancer, Tianjin, China,[19]Breast & Thyroid Surgery, Tianjin Union Medical Center, Tianjin, China
推荐引用方式(GB/T 7714)：
Jingzhu Zhao,Yihebali Chi,Chuanxiang Hu,et al.Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study[J].FRONTIERS IN ONCOLOGY.2022,12:doi:10.3389/fonc.2022.852032.
APA：
Jingzhu Zhao,Yihebali Chi,Chuanxiang Hu,Xiaohong Chen,Minghua Ge...&Xiangqian Zheng.(2022).Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study.FRONTIERS IN ONCOLOGY,12,
MLA：
Jingzhu Zhao,et al."Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study".FRONTIERS IN ONCOLOGY 12.(2022)
